Down syndrome results from having three copies of chromosome 21 instead of the usual two, and this extra genetic material disrupts development and organ function across nearly every system in the body. The core mechanism is deceptively simple: most genes on the extra chromosome produce roughly 50% more protein than they should, and that overproduction sets off a cascade of downstream effects, from how the brain wires itself before birth to how the immune system behaves decades later. But the full picture is far more layered than “one extra chromosome equals one set of symptoms,” because individual genes on chromosome 21 contribute to specific problems in specific organs, and some of those contributions are only now being untangled.
How the Extra Chromosome Gets There
The vast majority of Down syndrome cases, roughly 95%, arise from a type of error called nondisjunction, where chromosome 21 fails to separate properly during the formation of an egg or sperm cell. The result is a gamete carrying two copies of chromosome 21 instead of one. When that gamete is fertilized, the embryo ends up with three copies. Most of the time, the error happens in the egg rather than the sperm. Research from the Atlanta and National Down Syndrome Projects found that the association between advancing maternal age and trisomy 21 was restricted to errors in the egg; no such association appeared for errors originating in sperm or in post-fertilization cell division. In that study, mothers of infants with trisomy 21 due to a first-stage egg division error were about 8.5 times more likely to be 40 or older compared with mothers aged 20 to 24, and for second-stage errors the figure jumped to about 15 times more likely.1PubMed Central. Maternal age and risk for trisomy 21 assessed by the origin of chromosome nondisjunction: a report from the Atlanta and National Down Syndrome Projects
Why maternal age matters so much has been a long-standing puzzle, and part of the answer involves the way chromosomes exchange segments of DNA (a process called recombination) before they separate. When recombination occurs only near the far end of chromosome 21, the risk of a first-stage separation error increases regardless of the mother’s age. But when a single exchange happens close to the center of the chromosome, it interacts with age-related risk factors during the second stage of division, making errors in older eggs substantially more likely.2PubMed Central. New Insights into Human Nondisjunction of Chromosome 21 in Oocytes This pattern has been confirmed across multiple populations, pointing to a consistent interplay between the placement of these DNA exchanges and maternal age.3PubMed Central. Etiology of Down syndrome: Evidence for consistent association among altered meiotic recombination, nondisjunction, and maternal age across populations
A small fraction of cases involve a different mechanism: a Robertsonian translocation, in which the long arm of chromosome 21 attaches to another chromosome (often chromosome 14), so the extra genetic material is carried silently in a parent’s cells and passed to the child. Rarer still is mosaic trisomy 21, where the error happens after fertilization and only some cells carry three copies. In mosaic cases, the severity of symptoms can vary widely depending on what proportion of cells are affected. One study comparing oxidative stress markers across all three types found that individuals with mosaic trisomy 21 had oxidative stress levels that depended directly on the percentage of trisomic versus normal cells, unlike those with full trisomy or translocation trisomy, who consistently showed elevated levels.4PubMed. Lipid peroxidation in Down syndrome caused by regular trisomy 21, trisomy 21 by Robertsonian translocation and mosaic trisomy 21
The Gene Dosage Problem
The central idea behind Down syndrome pathophysiology is straightforward: three copies of a gene tend to produce roughly one and a half times the normal amount of protein. Because chromosome 21 contains several hundred genes, that modest overproduction adds up across many pathways at once. Genomic studies have confirmed that this “gene dosage” effect is generally what happens, though there is some variability between individuals. Some genes on the extra chromosome are overexpressed more than expected, others less, and this variability helps explain why no two people with Down syndrome have exactly the same constellation of features.5PubMed Central. Gene-dosage effects in Down syndrome and trisomic mouse models
This matters because it means Down syndrome is not one disease with one mechanism. It is a collection of effects driven by the overexpression of many different genes, each contributing to different organ systems. Some of the most impactful genes on chromosome 21 have been identified and linked to specific features of the condition, and understanding those links is where much of the current research is focused.
Key Genes and What They Do
DYRK1A and Cognitive Development
One of the most studied genes on chromosome 21 is DYRK1A, which encodes an enzyme involved in brain development. When this gene is overexpressed, it disrupts how brain cells develop during fetal life. Research in a mouse model of Down syndrome showed that extra DYRK1A pushes developing brain stem cells toward becoming support cells (astrocytes) rather than neurons. The result is fewer neurons and more astrocytes in the developing brain, which contributes to the cognitive challenges seen in Down syndrome.6PubMed Central. DYRK1A overexpression enhances STAT activity and astrogliogenesis in a Down syndrome mouse model Overexpression of DYRK1A has been directly linked to cognitive impairment as a key feature of the syndrome.7PubMed Central. Down syndrome and DYRK1A overexpression: relationships and future therapeutic directions
APP and Early Alzheimer’s Disease
The amyloid precursor protein (APP) gene also sits on chromosome 21. In the general population, buildup of amyloid protein fragments in the brain is a hallmark of Alzheimer’s disease. People with Down syndrome produce extra APP throughout their lives, and as a consequence, amyloid plaques begin accumulating in their brains far earlier than in the general population. By their 40s, most adults with Down syndrome show the brain pathology of Alzheimer’s, and many develop clinical dementia. A study of a rare individual with partial trisomy 21 who lacked the extra copy of APP found no evidence of Alzheimer’s disease, confirming that the APP gene specifically is required for this connection.8PubMed Central. Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer’s Disease: The Role of APP
SOD-1 and Oxidative Stress
Chromosome 21 encodes the enzyme copper-zinc superoxide dismutase (SOD-1), which is part of the body’s defense against reactive oxygen molecules. Counterintuitively, having too much of this particular antioxidant enzyme creates problems. Overproduction of SOD-1 generates an imbalance in the chemical reactions that handle oxygen inside cells, leading to increased oxidative stress rather than decreased. This oxidative imbalance is one of the most consistently documented features of Down syndrome at the cellular level and has been called a “phenotypic hallmark” of the condition.9PubMed. Oxidative stress and mitochondrial dysfunction in Down syndrome Studies have confirmed that cells from people with trisomy 21 produce significantly more reactive oxygen species from their mitochondria compared to controls.10PubMed. Evidence for increased mitochondrial superoxide production in Down syndrome
Interferon Receptors and Immune Dysregulation
Chromosome 21 happens to carry four of the six genes that encode interferon receptors, the cellular docking points for interferon signaling molecules that regulate immune responses. Having extra copies of these receptor genes means cells in people with Down syndrome are hypersensitive to interferon signals. This chronic interferon overactivation has been linked to the elevated rates of autoimmune conditions seen in Down syndrome, including thyroid disease, celiac disease, and type 1 diabetes.11PubMed Central. Down Syndrome and Autoimmune Disease Whole-blood analysis has demonstrated that this interferon receptor overexpression leads to chronic interferon hyperactivity and inflammation.12Nature Genetics. Triplication of the interferon receptor locus contributes to hallmarks of Down syndrome in a mouse model The same interferon hypersensitivity is thought to contribute to the predisposition for Alzheimer’s-like neurodegeneration through neuroinflammation.13PubMed Central. Autoimmune Mechanisms of Interferon Hypersensitivity and Neurodegenerative Diseases: Down Syndrome
How the Brain Develops Differently
The gene-level disruptions described above translate into measurable differences in brain structure that begin before birth. Imaging studies of children with Down syndrome consistently show smaller total brain volume, along with specific reductions in the frontal lobe, temporal lobe, hippocampus, and cerebellum even after accounting for the overall size difference.14PubMed Central. Pediatric brain development in Down syndrome: A field in its infancy
The cerebellum, which is critical for motor coordination, learning, and some aspects of language, is especially affected. Studies of fetal tissue at 17 to 21 weeks of gestation found that the cerebellum in Down syndrome fetuses had 25% to 50% fewer cells across all layers. The deficit was driven by reduced cell proliferation rather than increased cell death, meaning precursor cells simply divided less often.15PubMed Central. Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with down syndrome This pattern of impaired neurogenesis, not cell destruction, appears to be a widespread feature of brain development in trisomy 21.
Mitochondrial Dysfunction and Accelerated Aging
The oxidative stress created by SOD-1 overexpression does not exist in isolation. It feeds into a broader problem with mitochondria, the structures inside cells that generate energy. In Down syndrome, mitochondria show structural and functional abnormalities: disrupted energy production, impaired internal recycling mechanisms, and a general state of metabolic strain. This mitochondrial imbalance is now viewed as a driver of accelerated aging in Down syndrome, converging with cellular senescence and neuroinflammation to speed up Alzheimer’s-like brain pathology.16PubMed Central. Mitochondrial Imbalance in Down Syndrome: A Driver of Accelerated Brain Aging?
Molecular evidence backs up the idea that aging is genuinely accelerated, not just subjectively apparent. Using an “epigenetic clock” that measures chemical modifications to DNA, researchers found that blood and brain tissue from people with Down syndrome is on average 6.6 years older than their actual age.17PubMed Central. Accelerated epigenetic aging in Down syndrome This acceleration begins before birth: newborns with Down syndrome already show epigenetic age acceleration of roughly 244 days compared to newborns without the condition.18PubMed Central. Accelerated epigenetic aging in newborns with Down syndrome This prenatal head start on aging has implications for immune function, wound healing, and the early onset of Alzheimer’s disease.
Congenital Heart Defects
About 40% of infants with Down syndrome are born with congenital heart disease, compared to roughly 0.3% in the general newborn population. Atrioventricular septal defects, where the walls and valves between the heart’s four chambers fail to form properly, are the most characteristic type.19PubMed Central. Down Syndrome with Complete Atrioventricular Septal Defect, Hypertrophic Cardiomyopathy, and Pulmonary Vein Stenosis Researchers have looked for specific genetic variants that might explain why some individuals with trisomy 21 develop heart defects and others do not, but a genome-wide study found no common genetic variants with large effect size that account for the increased risk. Instead, the elevated susceptibility appears to arise from many variants of small-to-moderate effect, pointing to a complex genetic architecture even within an already genetically susceptible population.20G3 Genes|Genomes|Genetics. Genome-Wide Association Study of Down Syndrome-Associated Atrioventricular Septal Defects
One chromosome 21 gene linked to heart tissue is RCAN1, which regulates an enzyme called calcineurin that plays a role in cardiac remodeling and mitochondrial dynamics in heart cells.21PubMed Central. Down Syndrome Critical Region 1 Gene, Rcan1, Helps Maintain a More Fused Mitochondrial Network RCAN1 overexpression is involved in both the development and maintenance of the cardiovascular system.22PubMed Central. RCAN1 in cardiovascular diseases: molecular mechanisms and a potential therapeutic target Still, the 60% of people with Down syndrome who are born without heart defects underscore that trisomy 21 alone does not inevitably cause them; background genetic variation and environmental factors during fetal development clearly modify the outcome.
Gastrointestinal and Endocrine Effects
Gastrointestinal anomalies are common in Down syndrome, though less so than heart defects. Duodenal atresia, where the first part of the small intestine fails to develop an open channel, occurs in about 1% to 5% of babies with Down syndrome, and roughly a quarter to a third of all infants born with duodenal atresia have Down syndrome.23PubMed Central. Congenital duodenal obstruction associated with Down’s syndrome presenting with hematemesis Other gastrointestinal defects include esophageal atresia and Hirschsprung disease, each arising from different developmental processes at different stages of fetal growth. Esophageal atresia results from failed separation of the esophagus and trachea around four to five weeks of gestation; Hirschsprung disease involves the failure of nerve cells to migrate into the walls of the intestine between the fifth and twelfth weeks.24PubMed Central. Congenital gastrointestinal defects in Down syndrome: a report from the Atlanta and National Down Syndrome Projects
Thyroid dysfunction is another frequent finding. Even children and adolescents with Down syndrome who are technically within the normal range for thyroid function show measurably higher levels of thyroid hormones and thyroid-stimulating hormone compared to peers without the condition. These subtle differences in thyroid sensitivity appear to correlate with metabolic syndrome markers: one study found metabolic syndrome in 12% of children and adolescents with Down syndrome who were otherwise considered to have normal thyroid levels, with thyroid hormone measures correlating to blood sugar, triglycerides, and cholesterol values.25PubMed. Thyroid function, sensitivity to thyroid hormones, and metabolic syndrome in euthyroid children and adolescents with Down syndrome
Blood Disorders and Leukemia Risk
Down syndrome confers a distinctive pattern of blood cell abnormalities. Newborns with trisomy 21 sometimes develop a transient myeloproliferative disorder, in which the body overproduces certain blood cells. This condition usually resolves on its own within a few months, but a subset of affected children later develop acute megakaryoblastic leukemia, a form of blood cancer that is otherwise exceedingly rare in children. Research has shown that the leukemic cells in nearly all of these cases carry mutations in the GATA1 gene, which encodes a transcription factor essential for normal blood cell development.26PubMed Central. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia GATA1 is not on chromosome 21 itself (it sits on the X chromosome), but the trisomic background creates conditions in which GATA1 mutations are more likely to drive malignant transformation. Laboratory work using a chromosome-silencing approach confirmed that correcting the trisomy in stem cells normalized the overproduction of the blood cell types involved.27PubMed Central. Trisomy silencing by XIST normalizes Down syndrome cell pathogenesis demonstrated for hematopoietic defects in vitro
Bone and Musculoskeletal Problems
People with Down syndrome tend to have lower bone density than the general population, and this deficit begins early. Unlike the bone loss that occurs with aging in the general population, skeletal problems in Down syndrome appear rooted in developmental processes: bone-forming cells (osteoblasts) are less active, while bone-removing cells (osteoclasts) function normally, creating a net deficit in bone building.28PubMed Central. Skeletal Dynamics of Down Syndrome: A Developing Perspective Both human studies and animal models confirm reduced bone growth rates and delayed bone maturation.29PubMed. The aetiology of atypical bone health in individuals with Down syndrome
Exercise can help, though the response is blunted. A year-long physical training program in children and adolescents with Down syndrome produced measurable gains in bone mineral content at the spine and hip, but the improvements were smaller than what is typically reported in children without the condition.30PubMed. The bone tissue of children and adolescents with Down syndrome is sensitive to mechanical stress in certain skeletal locations: a 1-year physical training program study The joint laxity and low muscle tone characteristic of Down syndrome also contribute to orthopedic challenges, from flat feet to spinal instability at the top of the neck.
Hearing Loss
Hearing difficulties are common throughout childhood in Down syndrome, with conductive hearing loss (caused by fluid or structural issues in the middle ear) being the most frequent type. The narrow ear canals and increased susceptibility to ear infections that come with the characteristic facial anatomy contribute to this. But sensorineural hearing loss, which involves damage to the inner ear or auditory nerve, also occurs and tends to be progressive.31PubMed. Characteristics and Progression of Hearing Loss in Children with Down Syndrome Mixed hearing loss, combining both conductive and sensorineural components, is likewise associated with a declining trajectory over time. Because hearing problems directly affect language development and learning, regular audiological monitoring from infancy is a standard part of care.
Mouse Models and What They Reveal
Much of what researchers know about individual gene contributions comes from mouse models. Mice do not have a chromosome 21, but the genes found on human chromosome 21 are spread across three mouse chromosomes. Researchers have engineered mice that carry extra copies of various segments of those chromosomes to mimic different aspects of trisomy 21. The most widely used model for decades, the Ts65Dn mouse, is trisomic for about 90 human chromosome 21 gene equivalents but also carries roughly 35 extra genes that have nothing to do with Down syndrome, which complicates interpretation.32PubMed Central. Rodent models in Down syndrome research: impact and future opportunities
Newer models have improved fidelity. The TcMAC21 mouse carries nearly the entire long arm of human chromosome 21 as a freely segregating extra chromosome and recapitulates a striking range of Down syndrome features: small stature, cerebellar underdevelopment, facial differences, heart septal defects, elevated APP expression, and learning and memory deficits.33eLife. A non-mosaic transchromosomic mouse model of Down syndrome carrying the long arm of human chromosome 21 These models are indispensable for testing therapeutic strategies because they allow researchers to link specific gene dosage changes to specific organ-level effects and then attempt to reverse them.
Experimental Approaches to Correcting Gene Dosage
Two broad therapeutic strategies are being explored at the research level. The more ambitious is chromosome silencing using XIST, the gene that naturally inactivates one of the two X chromosomes in female cells. Researchers have shown that inserting an XIST gene into one of the three copies of chromosome 21 in stem cells derived from a person with Down syndrome can broadly suppress gene expression from that chromosome, effectively converting trisomic cells into functionally disomic ones.34PubMed Central. Trisomy silencing by XIST: translational prospects and challenges In laboratory tests, this approach corrected the overproduction of blood cell types linked to Down syndrome-associated leukemia.27PubMed Central. Trisomy silencing by XIST normalizes Down syndrome cell pathogenesis demonstrated for hematopoietic defects in vitro Translating this to a living person remains a formidable challenge, since it would require modifying trillions of cells.
A more targeted approach focuses on individual genes. Because DYRK1A overexpression is a major driver of cognitive features, inhibiting the DYRK1A enzyme has attracted attention. A green tea compound called epigallocatechin gallate (EGCG) acts as a DYRK1A inhibitor. In mouse models, EGCG rescued cognitive deficits, and a pilot study in people with Down syndrome showed improvements in memory recognition and working memory.35PubMed. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans Researchers are now developing synthetic compounds that retain EGCG’s mechanism of action but with improved potency and selectivity. One such compound corrected biochemical and behavioral defects in a Down syndrome mouse model.36PubMed. EGCG-like non-competitive inhibitor of DYRK1A rescues cognitive defect in a down syndrome model These are still early-stage efforts, but they illustrate a shift toward treating specific molecular consequences of trisomy 21 rather than the trisomy itself.
Why the Same Genetic Cause Produces Such Variable Outcomes
One of the most striking things about Down syndrome is how different two people with the same trisomy can be. Some individuals have severe heart defects and significant intellectual disability; others have structurally normal hearts, attend mainstream classrooms, and live semi-independently. Several factors drive this variability. Mosaic trisomy 21, where only a fraction of cells carry the extra chromosome, produces milder effects that scale with the proportion of trisomic cells. But even among people with full trisomy, the rest of their genome matters. The genome-wide study of heart defects in Down syndrome found that background genetic variants of small-to-moderate effect size collectively influence whether a given individual develops a septal defect or not.20G3 Genes|Genomes|Genetics. Genome-Wide Association Study of Down Syndrome-Associated Atrioventricular Septal Defects Epigenetic variation adds another layer, as the degree of accelerated epigenetic aging differs between individuals and may influence which age-related complications appear and when.
The interferon receptor story offers another window into variability. While chromosome 21 carries four interferon receptor genes, the downstream autoimmune consequences are not uniform. Some individuals develop Hashimoto’s thyroiditis, others celiac disease, others type 1 diabetes, and many develop none of these.11PubMed Central. Down Syndrome and Autoimmune Disease Which autoimmune condition emerges, if any, likely depends on interactions between the interferon hypersensitivity and the individual’s other immune-related genes and environmental exposures. This kind of combinatorial complexity is why a single chromosomal abnormality produces a syndrome, a collection of possible features, rather than a uniform disease.